D. Gary Gilliland's most recent trade in Laboratory Corp. Of America Holdings was a trade of 897 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 897 | 897 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 8,656 (0%) | 0% | - | Common Stock | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 0 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | Gilliland D. Gary | Director | Sale of securities on an exchange or to another person at price $ 241.00 per share. | 02 Dec 2024 | 1,000 | 7,712 (0%) | 0% | 241 | 241,000 | Common Stock |
| Nuvalent Inc - Ordinary Sh... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 3,789 | 3,789 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,499 | 2,499 | - | 0 | Class A Common Stock | |
| Laboratory Corp. Of Americ... | Gary D. Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 8,712 (0%) | 0% | - | Common Stock | |
| Laboratory Corp. Of Americ... | D. Gilliland Gary | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 944 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | Gary D. Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 944 | 1,891 | - | - | Restricted Stock Unit | |
| Nuvalent Inc - Ordinary Sh... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 7,765 (0%) | 0% | - | Common Stock | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit | |
| Nuvalent Inc - Ordinary Sh... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 742 | 742 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 7,023 (0%) | 0% | - | Common Stock | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 0 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Sale of securities on an exchange or to another person at price $ 302.25 per share. | 15 Dec 2021 | 357 | 6,395 (0%) | 0% | 302.2 | 107,903 | Common Stock |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Sale of securities on an exchange or to another person at price $ 302.26 per share. | 15 Dec 2021 | 100 | 6,295 (0%) | 0% | 302.3 | 30,226 | Common Stock |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Sale of securities on an exchange or to another person at price $ 302.28 per share. | 15 Dec 2021 | 25 | 6,270 (0%) | 0% | 302.3 | 7,557 | Common Stock |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Sale of securities on an exchange or to another person at price $ 302.33 per share. | 15 Dec 2021 | 18 | 6,252 (0%) | 0% | 302.3 | 5,442 | Common Stock |
| Nuvalent Inc - Ordinary Sh... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 43,000 | 60,412 | - | - | Stock Option (Right to Buy) | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 6,752 (0%) | 0% | - | Common Stock | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 986 | 771 | - | - | Restricted Stock Unit | |
| Laboratory Corp. Of Americ... | D. Gary Gilliland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 771 | 1,757 | - | - | Restricted Stock Unit |